← Leaderboards
Stryder Medoah Meadows
Tulane University Of Louisiana
$3,180,564
Attributed
$4,541,627
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,541,627 · 2
By mechanism
R01$4,541,627 · 2
Top collaborators
- Philippe Marambaud4 shared
Most similar at Tulane University Of Louisiana
Same institution · by research overlap
- Liang Ma$10,259,986
- Mario Tomas Philipp$11,469,177
- Angela Marie Crist$37,400
- Adella Patience Boudreaux Guidroz$98,512
- Shreya Bavishi$98,512
Others in their field
Other Emerging Leaders on “Hereditary Hemorrhagic Telangiectasia”
- Marie E Faughnan · University Of California, San Francisco$1,862,091
- Sonia M Thomas · Research Triangle Institute$1,613,863
- Kayla Branyan-Schroer · University Of California, San Francisco$209,537
- Daniel Snellings · Duke University$71,000
- Angela Marie Crist · Tulane University Of Louisiana$37,400
Research focus
Hereditary Hemorrhagic TelangiectasiaMouse ModelGeneticGenetic TranscriptionLinkMolecularEffective TherapyEndoglinDefectGenetic DiseasesArteriovenous MalformationAffectAngiopoietin-2Loss Of Function MutationAngiopoietinsAnemiaBlood VesselsAnimal ModelAneurysmActivin Receptor-Like Kinase 1ArteriesDesignCessation Of LifeNew Therapeutic Target
Grant awards (9)
Angiopoietin-2 Signaling Targeted Therapeutics for Arteriovenous Malformations$671,700
R01 · FY2025 · HL · contact PI
Angiopoietin-2 Signaling Targeted Therapeutics for Arteriovenous Malformations$664,047
R01 · FY2024 · HL · contact PI
Angiopoietin-2 Signaling Targeted Therapeutics for Arteriovenous Malformations$683,964
R01 · FY2023 · HL · contact PI
Angiopoietin-2 Signaling Targeted Therapeutics for Arteriovenous Malformations$702,416
R01 · FY2022 · HL · contact PI
Molecular mechanisms underlying Arteriovenous Malformations associated with HHT$380,000
R01 · FY2022 · HL · contact PI
Molecular mechanisms underlying Arteriovenous Malformations associated with HHT$380,000
R01 · FY2021 · HL · contact PI
Molecular mechanisms underlying Arteriovenous Malformations associated with HHT$380,000
R01 · FY2020 · HL · contact PI
Molecular mechanisms underlying Arteriovenous Malformations associated with HHT$340,875
R01 · FY2019 · HL · contact PI
Molecular mechanisms underlying Arteriovenous Malformations associated with HHT$338,625
R01 · FY2018 · HL · contact PI